Physician

Victor Wady Melgen, M.D.

According to 2025 Medicare claims, Victor Melgen, M.D. (NPI: 1386693331) practices medical oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32763-8399. Melgen is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Melgen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 832 traditional Medicare patients, billed 275,158 HCPCS/CPT codes, and received $4,547,600 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,290 prescription claims across 390 beneficiaries totaling $6,114,768 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 40 claims. Open Payments data shows 141 records totaling $2,897. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,503,938 and ending at $4,547,600. Concurrently, Part D prescription costs have risen steadily, from $2,546,627 to $6,114,768. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	841	254,387	$2,503,938
2016	849	328,625	$3,258,050
2017	872	310,758	$3,567,105
2018	812	380,781	$3,788,350
2019	783	372,004	$3,706,247
2020	719	431,057	$4,042,725
2021	761	291,194	$3,447,432
2022	717	243,957	$2,460,431
2023	808	269,593	$3,485,293
2024	832	275,158	$4,547,600

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	290	1,934	$2,546,627
2016	280	2,049	$3,064,090
2017	318	2,164	$3,308,484
2018	299	2,129	$4,232,870
2019	316	2,170	$4,965,969
2020	325	1,917	$3,848,157
2021	303	1,861	$3,788,767
2022	291	1,706	$3,734,965
2023	367	2,094	$4,197,098
2024	390	2,290	$6,114,768

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	42	$7,595
2017	N/R	14	$807
2018	N/R	72	$6,877
2019	N/R	35	$956
2020	N/R	29	$1,845
2021	N/R	68	$5,055
2022	N/R	40	$1,495
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	375	1,023	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	410	651	$63
96372	Injection of drug or substance under skin or into muscle	241	973	$10
36415	Insertion of needle into vein for collection of blood sample	666	2,373	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	658	2,513	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	124	3,262	$2,277,419
Imbruvica	Ibrutinib	42	1,176	$637,452
Pomalyst	Pomalidomide	21	588	$483,387
Erleada	Apalutamide	22	660	$311,030
Lorbrena	Lorlatinib	12	360	$245,448

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	141	$2,897	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Victor Wady Melgen, M.D.?

Tedicare shows public-source Medicare data for Victor Wady Melgen, M.D. (NPI 1386693331), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Victor Wady Melgen, M.D. have ACO affiliation data?

Victor Wady Melgen, M.D. is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Victor Wady Melgen, M.D.?

Victor Wady Melgen, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Victor Wady Melgen, M.D. have Open Payments data?

Victor Wady Melgen, M.D. has 141 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.